Charles River Labs stock hits fresh 52-week high as Medigen vaccine deal boosts sentiment
Published on 08/20/2026 at 20:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. (ISIN US1591881009) stock has pushed to a new 52-week high in August 2026, with shares touching $294.68 and recently trading at $294.93 according to market data as of August 20, 2026. This strength follows a new collaboration on an enterovirus vaccine candidate and comes on the heels of raised full-year 2026 guidance after the company reported its second-quarter 2026 results.
Vaccine partnership lifts growth narrative
On August 20, 2026, the company announced a collaboration with Medigen Vaccine Biologics Corp. to support development of a next-generation multivalent enterovirus vaccine, using its next-generation sequencing and analytical platforms to characterize viral seed stocks and support regulatory submissions for clinical trials. The Business Wire release on the Medigen partnership describes how Charles River will provide chemistry, manufacturing and controls support and nonclinical studies to back an investigational new drug application.
According to an item published on August 20, 2026, on a market news portal, the same partnership has been highlighted as part of the companys broader offering in vaccine development solutions, underscoring demand from biopharma clients for outsourcing complex analytical and safety testing work. Coverage of the Medigen collaboration notes that the stock showed a positive reaction in recent trading, with the share price indicated higher in pre-market and regular-session quotes on August 19 and August 20, 2026.
Shares mark a new 52-week high
Market data compiled on August 20, 2026, show that Charles River Laboratories stock reached a new 52-week high of $294.68, with the last reported trading level at $294.93, just above the previous peak of $294.56. A detailed 52-week high report emphasizes that this new high reflects a strong uptrend over the past year, with the shares having gained 90.12 percent over that period.
Another real-time quote snapshot for the shares lists a last close at $290.00 on August 19, 2026, with an indicated pre-market move that day showing the shares at $286.00 before the regular session, underlining that the latest push above $294 came after that close. The CRL quote page records the regular-session close at $290.00 on August 19, 2026, and intraday price changes into the next session. For investors, the fact that the current price of roughly $295 stands just above the prior 52-week peak of $294.56 illustrates how the stock has broken through technical resistance in August 2026.
A separate valuation-focused analysis dated August 20, 2026, observes that Charles River shares rose 3.9 percent on August 19, 2026, to $290.00, and compares this level with an estimated intrinsic value measure of $194.35 per share. The valuation commentary concludes that at $290.00 the stock traded 49.2 percent above that intrinsic value estimate, signaling that the latest 52-week high has pushed valuation well beyond that metric.
Q2 2026 earnings and guidance underpin momentum
Beyond short-term price action, the latest reported financials and guidance give more color on why sentiment has improved. A corporate news summary dated August 20, 2026, points back to the companys earnings release on August 5, 2026, for the second quarter and first half of 2026. This summary of the earnings and guidance notes that Charles River reported second-quarter 2026 results for the period ended June 27, 2026, and simultaneously lifted its full-year 2026 outlook.
According to that overview, the company reported that non-GAAP earnings and revenue for fiscal Q2 2026 declined compared with the prior-year period but still came in aligned with its updated outlook. The same summary states that management raised its 2026 guidance following the quarter, signaling confidence that demand in key business segments will improve over the remainder of the year. While the report does not enumerate every line item, the combination of modest short-term pressure and a higher full-year outlook has provided a fundamental backdrop for the share price strength.
The same news compilation indicates that at the time of the August 20, 2026, snapshot, the last close price for the shares was $290.00, with a separate real-time indication at $298.87, implying that the stock had moved higher after the Q2 2026 earnings and guidance announcement. Against the average analyst target price of $281.00 cited in that summary, the $290.00 close represented a premium of 3.10 percent, suggesting that the market price had already moved ahead of the consensus target by mid-August 2026.
Valuation and institutional interest context
The strong run in Charles River Laboratories stock during 2026 has drawn attention from valuation-oriented observers. In the valuation analysis that referenced the August 19, 2026, price of $290.00, the GF Value metric of $194.35 implied that the shares were trading 49.2 percent above that internal fair-value estimate. For investors, this comparison highlights how enthusiasm for the companys growth prospects, including its role in specialized research and vaccine development services, has driven the stock significantly above at least one quantitative valuation framework.
Contemporaneous coverage of broader market flows on August 20, 2026, notes that Charles River Laboratories appeared in lists of S&P 500 companies with some of the largest increases in institutional ownership in the second quarter of 2026, reinforcing the perception that professional investors have been adding exposure to the name during the recent rally. In combination with the rising price and guidance upgrade, higher institutional participation can add liquidity and potentially support the share price during periods of volatility.
Business profile: research and safety assessment services
Charles River Laboratories is best known for its portfolio of research models, discovery services, and safety assessment offerings that support pharmaceutical and biotechnology companies in preclinical development. The collaboration with Medigen on a multivalent enterovirus vaccine illustrates this positioning. In the partnership, Charles River will apply next-generation sequencing and other analytical platforms to thoroughly characterize the viral seed stocks and manufacturing processes required for the vaccine program, helping to ensure that the data packages submitted to regulators for clinical trial approval are comprehensive and robust.
Such contract research and development engagements are particularly important for smaller and mid-sized biotechnology companies that may not have the in-house capacity to perform complex safety testing, analytical development, and regulatory documentation. By providing integrated services from early discovery support through nonclinical studies, Charles River aims to capture a growing share of outsourced R&D budgets, which has been a long-term growth driver for the company and contributes to the rationale behind its raised guidance for 2026.
Stock level and recent trading
As of the latest data point on August 20, 2026, Charles River Laboratories stock is trading close to $295, slightly above the recent 52-week high of $294.68 and the prior peak of $294.56 identified in market reports. Against the $290.00 close on August 19, 2026, this represents a gain of around 1.7 percent into the new high, while the broader one-year performance stands at a 90.12 percent increase from levels seen in 2025.
The shares are listed on the New York Stock Exchange under the ticker CRL and trade in U.S. dollars. Based on an earlier market capitalization figure of $9.26 billion as of February 2026 from a company valuation database, the subsequent rally in the share price suggests that Charles River Laboratories equity value has increased meaningfully during 2026, even before accounting for any changes in share count. For investors, the combination of a new vaccine-development partnership, raised full-year guidance, and a breakout to new 52-week highs sets the stage for an active debate on whether the current premium to some valuation models is justified by the companys growth trajectory.
Read more
More on Charles River Labs stock and its recent partnership strategy is available in the detailed collaboration announcement and the latest earnings and guidance summaries from market data providers cited above.
Vaccine development services as a flagship offering
Within its broader portfolio, Charles River Laboratories positions its vaccine development services as a key growth area. The Medigen collaboration on a multivalent enterovirus vaccine serves as a representative example of how the company integrates next-generation sequencing, virology, bioanalytical testing, and nonclinical safety studies to help clients bring new vaccine candidates toward clinical trials.
By offering an integrated set of capabilities that spans from seed stock characterization and quality control through the nonclinical studies required for regulatory submissions, Charles River can capture value at multiple stages of the vaccine R&D lifecycle. Such services are particularly relevant at a time when public health agencies and private companies continue to invest in vaccines against both emerging infections and established pathogens, and when regulatory expectations for data quality remain high.
Current price context for investors
Based on the most recent consolidated quote snapshots, Charles River Laboratories stock last closed at $290.00 on the New York Stock Exchange on August 19, 2026, with subsequent intraday trading on August 20, 2026, lifting the shares to a 52-week high of $294.68 and a recent level of $294.93. These figures place the stock modestly above the average target price of $281.00 referenced in earnings and news summaries, and significantly above a GF Value intrinsic estimate of $194.35 used in one valuation framework. The divergence between market price and those benchmarks, alongside the companys raised 2026 guidance and expanding collaboration pipeline, forms the core of the current discussion over Charles River Labs stock.
Fact box
Company: Charles River Laboratories International, Inc.
ISIN: US1591881009
Ticker: CRL
Exchange: New York Stock Exchange
Price (as of August 19, 2026, 4:00 p.m. ET): $290.00 USD
Sector / Industry: Healthcare / Life sciences tools and services
